Selected article for: "direct interaction and small molecule"

Author: Li, Hui; Cheng, Chen; Li, Sumei; Wu, Yan; Liu, Zhihao; Liu, Mingjian; Chen, Jianxin; Zhong, Qiuyu; Zhang, Xuesha; Liu, Shuwen; Song, Gaopeng
Title: Discovery and structural optimization of 3-O-β-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections
  • Cord-id: x2cbdlp4
  • Document date: 2021_4_5
  • ID: x2cbdlp4
    Snippet: Currently, SARS-CoV-2 virus is an emerging pathogen that has posed a serious threat to public health worldwide. However, no agents have been approved to treat SARS-CoV-2 infections to date, underscoring the great need for effective and practical therapies for SARS-CoV-2 outbreaks. We reported that a focused screen of OA saponins identified 3-O-β-chacotriosyl OA benzyl ester 2 as a novel small molecule inhibitor of SARS-CoV-2 virus entry, via binding to SARS-CoV-2 glycoprotein (S). We performed
    Document: Currently, SARS-CoV-2 virus is an emerging pathogen that has posed a serious threat to public health worldwide. However, no agents have been approved to treat SARS-CoV-2 infections to date, underscoring the great need for effective and practical therapies for SARS-CoV-2 outbreaks. We reported that a focused screen of OA saponins identified 3-O-β-chacotriosyl OA benzyl ester 2 as a novel small molecule inhibitor of SARS-CoV-2 virus entry, via binding to SARS-CoV-2 glycoprotein (S). We performed structure-activity relationship profiling of 2 and discovered C-17-COOH of OA was an important modification site that improved both inhibitor potency toward SARS-CoV-2 and selectivity index. Then optimization from hit to lead resulted in a potent fusion inhibitor 12f displaying strong inhibition against infectious SARS-CoV-2 with an IC(50) value of 0.97 μM in vitro. Mechanism studies confirmed that inhibition of SARS-CoV-2 viral entry of 12f was mediated by the direct interaction with SARS-CoV-2 S2 subunit to block membrane fusion. These 3-O-β-chacotriosyl OA amide saponins are suitable for further optimization as SARS-CoV-2 entry inhibitors with the potential to be developed as therapeutic agents for the treatment of SARS-CoV-2 virus infections.

    Search related documents:
    Co phrase search for related documents
    • active compound and acute sars cov respiratory syndrome cov: 1, 2
    • active compound and low cytotoxicity: 1, 2
    • acute sars cov respiratory syndrome cov and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute sars cov respiratory syndrome cov and luciferase reporter: 1
    • acute sars cov respiratory syndrome cov and luciferase reporter gene: 1
    • lopinavir ritonavir and low cytotoxicity: 1
    • lopinavir ritonavir and luciferase reporter: 1
    • lopinavir ritonavir and luciferase reporter gene: 1
    • low cytotoxicity and luciferase reporter: 1